On May 12, Rongchang Biopharma issued an announcement that the company recently received the "Acceptance Notice" approved and issued by the National Medical Products Administration, and the clinical trial application of the new antibody-drug conjugate injection RC278 was accepted.

　　This drug was independently developed by the company and has First-in-Class/Best-in-Class potential. It can specifically identify new tumor targets and exhibit broad-spectrum anti-tumor activity, good safety and pharmacokinetic characteristics. It aims to provide new treatment options for patients with advanced solid tumors.

　　The acceptance number mentioned in the announcement is CXSL2500368, and the application is for the registration of clinical trials of domestically produced drugs. The company's board of directors bears legal responsibility for the authenticity, accuracy and completeness of the content of the announcement. Although the research and development prospects of the drug are promising, the announcement also reminds investors to pay attention to the high risks and uncertainties of pharmaceutical product research and development.

　　In the first quarter of 2025, Rongchang Bio achieved revenue of 526 million yuan and a net profit attributable to shareholders of the parent company of -254 million yuan.

https://finance.eastmoney.com/a/202505123402038165.html